Aromatase inhibitors in the treatment of early and advanced breast cancer

Heikki Joensuu, Bent Ejlertsen, Per E Lønning, Lars-Erik Rutqvist

Abstract

The third generation aromatase inhibitors anastrozole, exemestane, and letrozole have been compared with tamoxifen and other endocrine therapies in several studies in early and advanced breast cancer. These studies are reviewed in this report. Based on the available evidence, the panel recommends that adjuvant treatment with tamoxifen for 5 years should no longer be considered as the sole standard but that a third-generation aromatase inhibitor should be used either alone or in a sequence with tamoxifen in the adjuvant treatment of postmenopausal women with hormone-receptor-positive breast cancer. Third generation aromatase inhibitors may be considered as the first line therapy of hormone-receptor-positive advanced breast cancer in postmenopausal women, and they may also be used for preoperative therapy of breast cancer.

OriginalsprogEngelsk
TidsskriftActa Oncologica
Vol/bind44
Udgave nummer1
Sider (fra-til)23-31
Antal sider9
ISSN0284-186X
DOI
StatusUdgivet - 2005
Udgivet eksterntJa

Fingeraftryk

Dyk ned i forskningsemnerne om 'Aromatase inhibitors in the treatment of early and advanced breast cancer'. Sammen danner de et unikt fingeraftryk.

Citationsformater